lecubicin

Lecubicin (QHL-108) is a tumor microenvironment-activated prodrug of doxorubicin developed by Affinity Biopharma (Shanghai Qinheli Biotechnology). It is designed using a proprietary platform that conjugates doxorubicin to a peptide linker specifically cleaved by legumain (asparaginyl endopeptidase), an enzyme highly expressed in the tumor microenvironment and on the surface of tumor-associated macrophages, but minimally in normal tissues. This targeted activation mechanism is intended to increase the local concentration of doxorubicin within the tumor while significantly reducing systemic toxicities, particularly cardiotoxicity and myelosuppression, which are dose-limiting for conventional anthracyclines. Lecubicin is currently being evaluated in clinical trials for advanced solid tumors, including various subtypes of breast cancer.

Brand names

Legubicin

Other names

利卡比星Likabixinglegumain-activated doxorubicin